found that acute administration of the GLP-1RA exenatide resulted in reduced feelings of hunger in eight women with obesity
A patient may tolerate treatment for several weeks and then experience nausea, diarrhea, fullness, or reflux again after a clinician-directed dose increase
Muscle preservation during weight loss is a primary concern for GLP-1 users
Ozempic and Mounjaro are brand names used for those with diabetes
Common initial effects During the first one to two weeks, some users report: Increased gas and flatulence Mild bloating Slight changes in stool consistency Occasional mild nausea These symptoms are typical of any probiotic introduction and reflect the microbiome adjusting to new bacterial populations
Related Reporting on Weight Management Options For readers exploring the broader weight management landscape, the following third-party reporting provides additional context on different product categories: Analysis of telehealth GLP-1 supplier options Third-party reporting on compounded semaglutide access through telehealth platforms